Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Neoplasms 4Carcinoma, Non-Small-Cell Lung 3Thyroid Carcinoma, Anaplastic 2Respiratory Tract Neoplasms 2Colorectal Neoplasms 2Thyroid Neoplasms 1Neoplasm Metastasis 1Multiple Myeloma 1Lymphoma 1Liposarcoma 1Advanced Non-small Cell Lung Cancer (NSCLC) 1Advanced Cancer 1

Interventions

Iodine-131 21lenvatinib 17Magnetic Resonance Spectroscopy 17trametinib 13Sorafenib 13Thyrotropin Alfa 12pembrolizumab 11dabrafenib 11Thyroidectomy 10Surgical Procedures, Operative 10Thyroxine 9Paclitaxel 9vandetanib 8selpercatinib 8Sunitinib 7Nivolumab 7Fluorodeoxyglucose F18 7cabozantinib 6anlotinib 6Everolimus 6Biopsy 6pazopanib 5Vemurafenib 5Triiodothyronine 5Specimen Handling 5Saline Solution 5Radiotherapy 5Radiofrequency Ablation 5Iodine-124 5Cyclophosphamide 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Thyroid Neoplasms × efatutazone × Clear all
NCT02152137 2025-01-27

Inolitazone Dihydrochloride and Paclitaxel in Treating Patients With Advanced Anaplastic Thyroid Cancer

Alliance for Clinical Trials in Oncology

Phase 2 Completed
19 enrolled 13 charts
EndocrineHead & Neck

Thyroid Neoplasms, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡